Log in Free sign up

Ascendis Pharma A/S (ASND) News and press releases

News

From Benzinga Pro

What 14 Analyst Ratings Have To Say About Ascendis Pharma

Analyst Ratings

Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings:

Credit Suisse Maintains Outperform on Ascendis Pharma, Lowers Price Target to $123

News, Price Target, Analyst Ratings

Credit Suisse analyst Tiago Fauth maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and lowers the price target from $194 to $123.

Citigroup Maintains Buy on Ascendis Pharma, Lowers Price Target to $158

News, Price Target, Analyst Ratings

Citigroup analyst David Lebowitz maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $187 to $158.

Wells Fargo Maintains Overweight on Ascendis Pharma, Lowers Price Target to $176

News, Price Target, Analyst Ratings

Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $190 to $176.

SVB Leerink Maintains Outperform on Ascendis Pharma, Lowers Price Target to $174

News, Price Target, Analyst Ratings

SVB Leerink analyst Joseph Schwartz maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and lowers the price target from $193 to $174.

Stocks That Hit 52-Week Lows On Wednesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

During Wednesday's trading, 435 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 213 companies hit new 52-week lows.

The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL

Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

BofA Upgrades Ascendis Pharma After Promising TCP Phase 3 Data

Analyst Color, Upgrades, Price Target, Analyst Ratings

Following Ascendis Pharma’s (NASDAQ: ASND) reporting of positive topline Phase III data for its PaTHway trial of TransCon PTH (TCP) in adults with hypoparathyroidism, the likelihood of success of its TCP has increased from 60% to 75%, according to BofA Securities.

Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $197

News, Price Target, Analyst Ratings

Morgan Stanley maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $180 to $197.

B of A Securities Upgrades Ascendis Pharma to Buy, Raises Price Target to $161

News, Upgrades, Price Target, Analyst Ratings

B of A Securities analyst Tazeen Ahmad upgrades Ascendis Pharma (NASDAQ:ASND) from Neutral to Buy and raises the price target from $148 to $161.

SVB Leerink Maintains Outperform on Ascendis Pharma, Raises Price Target to $193

News, Price Target, Analyst Ratings

SVB Leerink analyst Joseph Schwartz maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $190 to $193.

Stocks That Hit 52-Week Lows On Monday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Monday, 671 companies achieved new lows for the year.

12 Health Care Stocks Moving In Monday's Pre-Market Session

Pre-Market Outlook, Markets, Movers

10 Biggest Price Target Changes For Monday

Penny Stocks, Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings

Wells Fargo raised the price target on Laredo Petroleum, Inc. (NYSE: LPI) from $72 to $113. Laredo Petroleum shares fell 2.8% to $71.00 in pre-market trading.

Ascendis Pharma's Hypoparathyroidism Trial Meets Primary, Secondary Endpoints

Biotech, News, Health Care, General

Ascendis Pharma A/S (NASDAQ: ASND)

Credit Suisse Maintains Outperform on Ascendis Pharma, Raises Price Target to $194

News, Price Target, Analyst Ratings

Credit Suisse analyst Tiago Fauth maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $188 to $194.

Expert Ratings For Ascendis Pharma

Analyst Ratings

Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings:

Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $180

News, Price Target, Analyst Ratings

Morgan Stanley analyst David Lebowitz maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $197 to $180.

Press releases

From Benzinga Pro

Ascendis Pharma A/S Reports First Quarter 2022 Financial Results

Earnings, Press Releases

Phase 3 PaTHway Trial top-line results demonstrated potential of TransCon™ PTH to become the first parathyroid replacement therapy for adults with hypoparathyroidismTransCon PTH U.S. FDA regulatory submission on

Ascendis Pharma A/S Announces First Quarter 2022 Financial Results and Business Update Conference Call on May 11

News, Press Releases

COPENHAGEN, Denmark, May 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) announced today that the company will hold a conference call and live webcast on Wednesday, May 11, 2022 at 4:30 p.m. Eastern Time

Ascendis Pharma A/S to Present New Endocrinology Results at Four Medical Meetings in May

News, Health Care, Press Releases

New data highlights include: - Phase 3 open-label extension study data for growth hormone-deficient children treated for 2.5 years with TransConTM hGH - Initial findings from research on comorbidities

Ascendis Pharma Announces Proposed Convertible Senior Notes Offering

COPENHAGEN, Denmark, March 23, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candidates that address

Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints

Health Care, Press Releases

– For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control (p-value <0.0001). – TransCon PTH demonstrated statistically significant improvements compared

Ascendis Pharma A/S Reports Full Year 2021 Financial Results and Provides a Business Update

Earnings, News, Press Releases

- Top-line results from PaTHway, a Phase 3 randomized study evaluating the safety, tolerability, and efficacy of TransCon™ PTH in adult hypoparathyroidism (HP) patients on track for this quarter - Demand for

Ascendis Pharma A/S Announces Full Year 2021 Financial Results and Business Update Conference Call on March 2

News, Press Releases

COPENHAGEN, Denmark, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Company will hold a conference call and live webcast on Wednesday, March 2, 2022 at 4:30 p.m. Eastern